Comparative contraceptive efficacy of the female condom and other barrier methods.
Because the research design for the clinical trial establishing the contraceptive efficacy of the female condom--a six-month life-table probability of failure of 15% (12% in the United States vs. 22% in Latin America)--did not include randomization with another method of contraception, no definite conclusion about its comparative efficacy is possible. Comparisons using other female barrier methods as historical controls, however, provide evidence that, among women in the United States, the contraceptive efficacy of the female condom during typical use is not significantly different from that of the diaphragm, the sponge or the cervical cap. The six-month probability of failure during perfect use of the female condom is 2.6% among U.S. women, similar to rates for the diaphragm and the cervical cap but significantly lower than that for the sponge. Meaningful comparisons with the male condom are not possible because of the lack of data from carefully controlled prospective clinical trials. Extrapolations from the results on contraceptive efficacy suggest that perfect use of the female condom may reduce the annual risk of acquiring the human immunodeficiency virus by more than 90% among women who have intercourse twice weekly with an infected male.
Woodrow Wilson School of Public and International Affairs, Princeton University, N.J.
J
J
Trussell
K
K
Sturgen
J
J
Strickler
R
R
Dominik
D002986:Clinical Trials as Topic; D017280:Condoms / Q000592:standards*; D003274:Contraceptive Devices, Female / Q000592:standards*; D005260:Female; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D007843:Latin America; D015993:Life Tables; D008297:Male; D010349:Patient Compliance; D012107:Research Design; D012307:Risk Factors; D014481:United States